Human Placental Lactogen (HPL)
Human placental lactogen (HPL), also referred to as human chorionic somatomammotropin (hCS), is a polypeptide hormone secreted by syncytiotrophoblast cells of the placenta during pregnancy. It plays a pivotal role in ensuring adequate fetal development and growth. Detectable levels of HPL appear around the 6th week of gestation, rapidly rising and typically reaching peak concentrations between the 13th and 34th weeks of pregnancy, with values generally ranging from 5,000–7,000 ng/mL at their maximum. These elevated levels are maintained steadily through late pregnancy, reflecting healthy placental function and adequate fetal development. Following childbirth, HPL levels rapidly decrease and become undetectable soon after delivery.
HPL exerts metabolic effects by increasing maternal insulin resistance, thus raising maternal blood glucose levels and ensuring a continuous supply of glucose and amino acids to the developing fetus. This insulin resistance occasionally results in gestational diabetes mellitus in susceptible women. HPL also binds to prolactin (PRL) receptors, facilitating breast development in preparation for lactation.
Clinically, HPL measurement serves as a valuable indicator of placental health and fetal well-being. Low HPL levels may reflect placental insufficiency, fetal distress, intrauterine growth restriction (IUGR), preeclampsia, or increased risk of adverse pregnancy outcomes. Conversely, significantly elevated HPL levels can indicate multiple pregnancies (such as twins) or gestational trophoblastic disease due to increased placental mass.
- Monitor placental health and fetal well-being during pregnancy
- Aid in the evaluation and management of gestational diabetes mellitus
- Evaluation of suspected gestational trophoblastic disease or multiple gestations
- Assist in assessing risk and monitoring progression of preeclampsia and intrauterine growth restriction (IUGR)
Increased in:
- Twin pregnancies
- Gestational trophoblastic disease
- Gestational diabetes mellitus
Decreased in:
- Intrauterine Growth Restriction
- Preeclampsia
- Stillbirth/ Miscarriage
Males and non-pregnant women: 0.0 – 0.1 mcg/mL
1st trimester: 0.2 – 2.1 mcg/mL
2nd trimester: 0.5 – 6.7 mcg/mL
3rd trimester: 4.5 – 12.8 mcg/mL
Immunoassay, enzyme immunoassay, enzyme-linked immunosorbent assay (ELISA).
Serum (Red top).
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: 90 days
- Int J Mol Sci. 2022 Dec 9;23(24):15621. [PMID: 36555258]
- J Pediatr Endocrinol Metab. 2000 Apr;13(4):343-56. [PMID: 10776988]
- Front Endocrinol (Lausanne). 2022 Sep 9;13:946539. [PMID: 36157466]
- Pediatr Res. 1993 Oct;34(4):439-42. [PMID: 8255674]